MADISON, Wis., Dec. 7 /PRNewswire/ -- ConjuGon(TM), a biotechnology company developing fundamentally new treatments for antibiotic-resistant bacterial infections, announced today that it has appointed Guillermo Herrera to its Board of Directors.
Mr. Herrera spent more than 24 years with Abbott Laboratories where his positions included Senior Vice President of International Operations, President of Abbott International. Mr. Herrera held other senior leadership positions, including Vice President, European Operations, and Vice President, Latin American and Canada Operations. He was elected an Abbott Corporate Vice President in 1996. Mr. Herrera currently is a Principal of the Rosetta Group, LLC (Lake Forest, Illinois), a biotechnology investment fund.
"Guillermo has great insights and expertise from his years working in proprietary pharmaceuticals," said ConjuGon CEO Christopher Price. "His experience in all aspects of pharmaceutical development, operations and marketing will be invaluable assets for ConjuGon. The ConjuGon Board of Directors, the management team, and I all look forward to working closely with Guillermo as we continue to develop our technology."
"The problem of antibiotic resistance is getting worse and worse every day," stated Mr. Herrera. "Fundamentally new technologies are critically needed to overcome a serious public health threat. I'm excited about working with ConjuGon in helping it bring new health care solutions to patients."
ConjuGon is developing fundamentally new technologies to combat the growing epidemic of antibioticresistant bacteria. Antibiotic resistance is a medical crisis, globally responsible for hundreds of thousands of deaths each year. ConjuGon's core technology is a new way to kill multi-drug resistant bacteria. The company is located in the MG&E Innovation Center in Madison, Wisconsin.
CONTACT: Sal Braico of ConjuGon, Inc., +1-608-441-2890,email@example.com